Prognostic Value of CD Markers in Immune Thrombocytopenic Purpura
NCT04311593 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 68
Last updated 2020-03-17
Summary
In this study, we will focus on the independent prognostic relevance of the expressions of CD38, CD4, CD56, CD11b and CD19 markers in immune cells with platelet changes in patients with newly diagnosed and chronic ITP.
Conditions
Interventions
- DIAGNOSTIC_TEST
-
CD4, CD19, CD38, CD56 and CD11b
measuring CD markers by flowcytometry
Sponsors & Collaborators
-
Assiut University
lead OTHER
Principal Investigators
-
Essam ELdeen abdmohsen mohammed, Professor · +201001971906
Eligibility
- Min Age
- 2 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-05-31
- Primary Completion
- 2021-05-31
- Completion
- 2021-08-31
More Related Trials
-
Prevalence of Thyroid Disorders in Patients With Immune Thrombocytopenic Purpura and Its Impact on Treatment
NCT07059910 ·Status: NOT_YET_RECRUITING
-
Immune Thrombocytopenia (ITP) Immune-Genetic Assessment
NCT01196884 ·Status: UNKNOWN
-
Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
NCT00454857 ·Status: COMPLETED
-
Steroid Resistance in Pediatric Immune Thrombocytopenic Purpura
NCT06601543 ·Status: NOT_YET_RECRUITING
-
Research of Predictive Factors to Immune Thrombopenic Purpura
NCT01648556 ·Status: COMPLETED ·Phase: NA
-
Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)
NCT06168851 ·Status: RECRUITING ·Phase: PHASE2
-
" Effect of Single-nucleotide Polymorphism of CD40 Gene rs1883832 C/T on the Risk of Immune Thrombocytopenic Purpura "
NCT05585944 ·Status: UNKNOWN ·Phase: NA
-
Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP)
NCT06838962 ·Status: RECRUITING ·Phase: PHASE2
-
Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)
NCT06107582 ·Status: RECRUITING
-
Immunological Aspect of Thrombotic Thrombocytopenic Purpura (TTP)
NCT06945861 ·Status: RECRUITING
-
Role of CD11a in Pathogenesis of Primary ITP and Effect of Immunosuppressive Therapy on Its Level
NCT03864796 ·Status: COMPLETED
-
Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10
NCT00168038 ·Status: COMPLETED ·Phase: PHASE3
-
Cognitive Status, Fatigue and Inflammation in Patients With Immune Thrombocytopenia (ITP)
NCT06665308 ·Status: COMPLETED
-
Explore the Relationship Between Platelet Count and Bleeding Score in ITP
NCT06273956 ·Status: RECRUITING
-
Study of Platelets Sialylation by Flow Cytometry for the Differential Diagnosis of ICT
NCT03421392 ·Status: COMPLETED
-
IL37,Tlymphocytes,NK Cells in Pathogenesis of ITP
NCT04482777 ·Status: UNKNOWN
-
Triple Therapy in Patients With Idiopathic Thrombocytopenic Purpura : What is Behind?
NCT04128358 ·Status: UNKNOWN ·Phase: NA
-
Cohort of Children With Acute Immune or Idiopathic Thrombocytopenic Purpura (ITP) : a Prospective Study in Pays De La Loire
NCT00331357 ·Status: UNKNOWN
-
Safety of Oral Thrombopoietin Receptor Agonist in Pediatric Chronic ITP
NCT05846529 ·Status: UNKNOWN
-
Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
NCT07297563 ·Status: RECRUITING ·Phase: PHASE2
-
Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura
NCT04323748 ·Status: RECRUITING ·Phase: PHASE1
-
The Outcome of the Thrombopoietin Receptor Agonists in Pediatric Patient With Persistent or Chronic ITP Unresonsive to Steroids
NCT06568913 ·Status: RECRUITING ·Phase: NA
-
Study of T Cells and Natural Killer Cells Expression in Patients With Immune Thrombocytopenic Purpura
NCT05093257 ·Status: UNKNOWN
-
Health-related Quality of Life and Fatigue in Adult Patients With Primary Immune Thrombocytopenic Purpura (pITP)
NCT01510873 ·Status: COMPLETED
-
Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)
NCT07063199 ·Status: RECRUITING ·Phase: PHASE2